Skip to main content
TipRanks
Go Ultimate75% OFF

Venture Life (17V) AI Stock Analysis

0 Followers
DE:17V

Venture Life

(Frankfurt:17V)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Balance Sheet StrengthThe sharp reduction in debt materially improves financial flexibility and lowers balance-sheet risk. A sizeable equity base gives Venture Life greater capacity to support product investment, withstand operating volatility, and pursue growth without relying heavily on external financing.
Negative Factors
Revenue VolatilityThe uneven revenue pattern makes forward earnings less predictable and complicates planning for inventory, marketing, and investment. A rebound is encouraging, but recurring swings would weaken confidence that recent growth represents a durable expansion of the underlying business.

Venture Life (17V) vs. iShares MSCI Germany ETF (EWG)

-5%0%5%10%15%20%25%30%DE:17V+24.41%EWG+4.05%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 81.42M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
15.7
Beta (1Y)
0.14
Revenue Growth
―
EPS Growth
―
Country
Germany
Employees
63
Sector
Consumer Defensive
Sector Strength
62
Industry
Medical - Pharmaceuticals

Venture Life Business Overview & Revenue Model

Company Description

Established in Bracknell, UK, in 2005, Venture Life Group plc is an international developer and marketer of diverse health and personal care items. The company's portfolio spans oral care products, dietary supplements, medical devices, dermo-cosmetic...

Venture Life Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

DE:17V against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:HLNGB:HLN63NeutralGBP 29.98B18.859.89%1.35%1.21%8.33%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
GB:STXGB:STX43NeutralGBP 32.76M-4.0864.57%―36.19%60.75%
GB:AGYGB:AGY41NeutralGBP 77.57M-1.391684.19%―8.77%-7.14%
GB:PXSGB:PXS40UnderperformGBP 16.54M-70.50-44.68%―-2.14%0.00%

* Consumer Defensive Sector Average

Performance Comparison

-50%0%50%100%DE:17VGB:AGYGB:PXSGB:STXGB:HLNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:17V and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:17VVenture Life0.790.1625.40%
GB:AGYAllergy Therapeutics1.23-8.13-86.90%
GB:PXSProvexis plc0.700.1016.14%
GB:STXShield Therapeutics3.05-3.70-54.81%
GB:HLNHaleon PLC341.90-27.81-7.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.